optinose
reports
third
quarter
financial
results
recent
operational
highlights
nasdaq
optn
company
reports
third
quarter
xhance
net
revenue
million
new
prescriptions
xhance
increased
second
quarter
conference
call
webcast
held
today
eastern
time
yardley
globe
newswire
optinose
nasdaq
optn
pharmaceutical
company
focused
patients
treated
ear
nose
throat
ent
allergy
specialists
today
reported
financial
results
three
nine
months
ended
september
provided
operational
updates
new
total
prescriptions
xhance
reached
quarterly
high
third
quarter
pleased
achievement
experiencing
challenging
environment
second
quarter
due
significant
declines
patient
volume
ent
allergy
offices
stated
ceo
peter
miller
result
increased
demand
improvement
net
revenue
per
prescription
xhance
net
revenues
million
exceeding
third
quarter
net
revenue
threshold
specified
debt
facility
open
option
draw
additional
million
add
cash
position
would
extend
cash
runway
enable
us
focus
growth
finally
excited
recent
events
believe
meaningfully
support
xhance
growth
potential
progress
include
kaléo
first
hit
field
october
grows
sales
reach
frequency
new
publication
brent
senior
professor
otolaryngology
vice
chair
academics
outreach
university
north
carolina
others
describes
value
xhance
population
patients
still
symptomatic
conventional
nasal
third
quarter
recent
highlights
total
new
xhance
prescriptions
number
fluticasone
propionate
prescriptions
increased
third
quarter
third
quarter
number
new
prescriptions
xhance
increased
second
quarter
third
quarter
kaléo
agreement
july
company
announced
signing
agreement
kaléo
pharmaceutical
company
dedicated
building
innovative
solutions
serious
medical
conditions
xhance
terms
agreement
kaléo
initiated
promotion
xhance
audience
healthcare
professionals
october
audience
includes
nearly
prescribers
half
outside
current
optinose
universe
approximately
healthcare
professionals
scientific
journal
publications
september
company
announced
publication
paper
titled
efficacy
exhalation
delivery
system
fluticasone
patients
remain
symptomatic
standard
nasal
steroid
sprays
international
forum
allergy
rhinology
journal
american
rhinologic
society
food
drug
administration
fda
approved
treatment
nasal
polyps
patients
years
age
older
marketed
trade
name
xhance
patients
whose
chronic
rhinosinusitis
complicated
nasal
polyps
june
company
announced
initiation
development
new
product
candidate
combine
company
proprietary
nasal
exhalation
delivery
system
eds
antiseptic
shown
third
party
vitro
studies
kill
virus
causes
company
performed
vitro
testing
candidate
antiseptic
formulation
reduction
reduction
virus
count
produced
addition
company
performing
tests
pathogens
expects
results
november
components
combination
product
candidate
including
active
drug
delivery
device
currently
commercially
available
company
anticipates
streamlined
accelerated
development
subsequent
new
drug
ind
submission
company
engaged
fda
regarding
ind
clinical
development
pathway
company
focused
supporting
initial
stages
development
within
current
operating
expense
guidance
intends
seek
grants
partnerships
sources
capital
fund
future
development
third
quarter
financial
results
net
product
revenues
company
generated
million
million
net
product
revenues
sales
xhance
three
nine
months
ended
september
respectively
costs
expenses
net
loss
three
nine
months
ended
september
research
development
expenses
million
million
respectively
selling
general
administrative
expenses
million
million
respectively
net
loss
three
nine
months
ended
september
million
per
share
basic
diluted
million
per
share
basic
diluted
respectively
cash
cash
equivalents
company
cash
cash
equivalents
million
september
corporate
guidance
operating
expenses
company
expects
total
gaap
operating
expenses
selling
general
administrative
expenses
research
development
expenses
range
million
company
expects
compensation
approximately
million
previously
company
expected
total
gaap
operating
expenses
selling
general
administrative
expenses
research
development
expenses
range
million
compensation
expected
approximately
million
chronic
sinusitis
clinical
trials
company
expects
results
clinical
trials
evaluating
xhance
potential
treatment
chronic
sinusitis
second
half
cash
cash
equivalents
company
expects
draw
million
cash
debt
facility
early
subject
continuing
meet
eligibility
requirements
company
host
conference
call
members
company
leadership
team
host
conference
call
presentation
discuss
financial
results
corporate
updates
beginning
eastern
time
today
participate
conference
call
please
dial
outside
addition
following
completion
call
telephone
replay
accessible
november
dialing
outside
entering
conference
id
simultaneous
webcast
call
presentation
accessed
visiting
investors
section
optinose
website
addition
replay
webcast
available
company
website
days
following
event
investor
conferences
chief
executive
officer
peter
miller
present
jefferies
virtual
london
healthcare
conference
november
et
additionally
miller
present
annual
piper
sandler
healthcare
conference
november
et
live
webcast
available
conference
investors
section
optinose
website
replay
available
days
following
conclusion
event
optinose
condensed
consolidated
statement
operations
thousands
except
share
per
share
data
unaudited
three
months
ended
nine
months
ended
september
september
revenues
net
product
revenues
licensing
revenues
total
revenues
costs
expenses
cost
product
sales
research
development
selling
general
administrative
total
costs
expenses
loss
operations
expense
net
loss
net
loss
per
share
common
stock
basic
diluted
weighted
average
common
shares
outstanding
basic
diluted
optinose
condensed
consolidated
balance
sheet
data
thousands
september
december
unaudited
cash
cash
equivalents
assets
total
assets
total
current
liabilities
debt
net
liabilities
total
stockholders
equity
total
liabilities
stockholders
equity
optinose
optinose
specialty
pharmaceutical
company
focused
serving
needs
patients
cared
ear
nose
throat
ent
allergy
specialists
optinose
offices
norway
learn
please
visit
follow
us
twitter
linkedin
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
historical
facts
hereby
identified
statements
purpose
include
among
others
statements
relating
impact
plans
regarding
uncertainty
caused
pandemic
potential
continued
xhance
growth
potential
benefits
kaléo
promotional
activities
potential
benefits
publication
paper
titled
efficacy
exhalation
delivery
system
fluticasone
patients
remain
symptomatic
standard
nasal
steroid
sprays
international
forum
allergy
rhinology
potential
benefits
product
candidate
expectation
additional
vitro
testing
data
november
development
funding
plans
expectations
expectation
draw
additional
million
pharmakon
note
purchase
agreement
february
subject
continuing
meet
eligibility
requirements
time
draw
plans
seek
approval
indication
xhance
treatment
chronic
sinusitis
expectation
results
chronic
sinusitis
trials
second
half
projected
company
gaap
operating
expenses
compensation
statements
regarding
company
future
operations
financial
performance
financial
position
prospects
objectives
future
events
statements
based
upon
management
current
expectations
assumptions
subject
number
risks
uncertainties
factors
could
cause
actual
results
events
differ
materially
adversely
indicated
statements
including
among
others
extent
duration
pandemic
impact
company
business
results
operations
financial
condition
physician
patient
acceptance
xhance
company
ability
maintain
adequate
reimbursement
xhance
market
access
market
opportunities
xhance
may
smaller
expected
effectiveness
kaléo
sales
representatives
promoting
xhance
risks
uncertainties
delays
relating
product
development
initiation
enrollment
completion
results
clinical
trials
regulatory
approval
process
risks
results
seen
preclinical
studies
may
replicated
humans
intense
competition
vaccines
therapies
company
ability
grow
xhance
prescriptions
net
revenues
unanticipated
costs
expenses
company
ability
meet
continued
eligibility
requirements
draw
additional
million
pharmakon
note
purchase
agreement
otherwise
comply
covenants
terms
note
purchase
agreement
risks
uncertainties
relating
intellectual
property
risks
uncertainties
factors
discussed
caption
item
risk
factors
elsewhere
company
recent
form
form
filings
securities
exchange
commission
available
result
cautioned
place
undue
reliance
statements
statements
made
press
release
speak
date
press
release
company
undertakes
obligation
update
statements
whether
result
new
information
future
developments
otherwise
references
senior
ba
schlosser
rj
bosso
j
soler
zm
efficacy
exhalation
delivery
system
fluticasone
patients
remain
symptomatic
standard
nasal
steroid
sprays
int
forum
allergy
rhinol
sept
doi
epub
ahead
print
optinose
investor
contact
jonathan
neely
